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creativecommons.org/licenses/by-nc-nd/Abstract Purpose: The addition of bisphosphonates to adjuvant therapy improves survival
in postmenopausal breast cancer (BC) patients. We report a meta-analysis of four randomised
trials of neoadjuvant chemotherapy (CT) þ/e zoledronic acid (ZA) in stage II/III BC to inves-
tigate the potential for enhancing the pathological response.
Methods: Individual patient data from four prospective randomised clinical trials reporting
the effect of the addition of ZA on the pathological response after neoadjuvant CT were
pooled. Primary outcomes were pathological complete response in the breast (pCRb) and in
the breast and lymph nodes (pCR). Trial-level and individual patient data meta-analyses were
done. Predefined subgroup-analyses were performed for postmenopausal women and patients
with triple-negative BC.
Results: pCRb and pCR data were available in 735 and 552 patients respectively. In the total
study population ZA addition to neoadjuvant CT did not increase pCRb or pCR rates. How-
ever, in postmenopausal patients, the addition of ZA resulted in a significant, near doubling of
the pCRb rate (10.8% for CT only versus 17.7% with CTþZA; odds ratio [OR] 2.14, 95% con-
fidence interval [CI] 1.01e4.55) and a non-significant benefit of the pCR rate (7.8% for CTf Clinical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
.R. Kroep).
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J.R. Kroep et al. / European Journal of Cancer 54 (2016) 57e6358only versus 14.6% with CTþZA; OR 2.62, 95% CI 0.90e7.62). In patients with triple-negative
BC a trend was observed favouring CTþZA.
Conclusion: This meta-analysis shows no impact from the addition of ZA to neoadjuvant CT
on pCR. However, as has been seen in the adjuvant setting, the addition of ZA to neoadjuvant
CT may augment the effects of CT in postmenopausal patients with BC.
ª 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The anti-tumour effect of bisphosphonates is still an issue
of debate. Recently, the Early Breast Cancer Trialists’
CollaborativeGroup (EBCTCG)meta-analysis in 17,791
patients demonstrated that adjuvant bisphosphonates
reduce bone metastases and improve survival in post-
menopausal women with early breast cancer (BC) [1].
Several studies have also suggested that the addition of
zoledronic acid (ZA) to chemotherapy (CT) in the neo-
adjuvant setting may be beneficial and result in increased
rates of pathological complete response (pCR) [2e4].
However, the body of evidence for this is limited due to
the low number of patients and relatively discordant
findings [2e5]. In the neoadjuvant subset of the AZURE
study, consisting of 205 patients with cT3 or cT4 disease
or biopsy-proven lymph node involvement, the pCR rate
nearly doubled in the cohort of patients who received ZA
(4 mg q3e4 weeks, six doses) as an adjunct to neo-
adjuvant CT. Aft et al. reported that ZA administration
resulted in a significant decrease in detectable dissemi-
nated tumour cells in patients with clinical stage II/III BC
treated with four cycles of neoadjuvant epirubicin plus
docetaxel, in comparison to patients who were treated
with CT only [3]. In contrast, the two comparative phase
III trials which were prospectively designed to evaluate
pCR rates following neoadjuvant CT with or without ZA
4mg intravenously at the beginning of each cycle failed to
show a beneficial effect in their stage II/III early BC
population [4,5]. However, in both of these studies a
numerical benefit was observed in postmenopausal
women specifically, seemingly concordant with the data
from the neoadjuvantAZURE subgroup analysis and the
adjuvant meta-analysis.
Together, study results support the hypothesis that
ZA may have an anti-tumour effect and that synergism
may occur with CT[6]. We report a meta-analysis of
individual patients data from all randomised studies that
have compared the use of ZA (4 mg, 4e6 doses, q3e4
weeks) combined with neoadjuvant CT versus no
bisphosphonate in patients with early BC.
2. Methods
2.1. Included studies
Patients from four prospective randomised studies were
included in this meta-analysis. The NEOZOTAC trialanalysed 246 patients which received six three-weekly
cycles of TAC CT (docetaxel, doxorubicin, cyclophos-
phamide with pegylated G-CSF within 24 h) with or
without ZA (4 mg intravenous [i.v.]). The JONIE1 trial
randomised 180 patients to receive neoadjuvant CT
(four three-weekly cycles FEC [5-fluorouracil, epi-
rubicin, cyclophosphamide] followed by 12 weekly cy-
cles paclitaxel) with or without seven infusions of ZA
4 mg. In the neoadjuvant subset of the AZURE study,
205 patients received neoadjuvant CT following local
guidelines, with or without ZA 4 mg, every 3e4 weeks,
for six doses. In the study by Aft et al. 119 patients (one
patient withdrew consent) received four cycles of intra-
venous neoadjuvant epirubicin plus docetaxel every 3
weeks, with granulocyte-stimulating factor support,
with or without ZA (4 mg i.v.). Time of zoledronate
infusion was after CT infusion in all of the studies. As
the timing of infusion was not specified no analysis was
done regarding the exact timing of infusion.
2.2. Variables collected from each study
Participating study groups were asked to provide patient
data on the following variables: oestrogen receptor
(ER)-status, progesterone receptor-status, cT-status,
cN-status, menopausal status, age, pathological com-
plete response in the breast (pCRb)-status, pathological
complete response in the breast and lymph nodes
(pCR)-status and allocated treatment. pCRb was
defined as absence of invasive tumour cells in the breast.
2.3. Statistical analysis
Patient characteristics in treatment arms were
compared with the Pearsons’s chi-square test, or if
applicable Fisher’s exact test, in case of categorical
variables or the ManneWhitney-U test in case of
continuous variables. Homogeneity of the treatment
effect among studies was tested using the Q statistic
and by calculating the I2-value. Data were analysed on
a trial-level as well as on individual patient level. Due
to the homogeneity of study effect sizes fixed-effects
models were used. For the trial-level approach, odds
ratios (OR) of each separate study were calculated,
correcting for the classical predictors ER-status and
cT-status (cN-status was not completely collected in
some studies). Pooling of ORs was performed using
inverse variance weighting.
Table 1
Patient and tumour characteristics of the pooled population.
Pooled population
N 750
Median age(range) 48 (25e75)
T-status T1/T2 374 (49.9)
T3/T4 375 (50.0)
Unknown 1 (0.1)
N statusa N- 223 (29.7)
Nþ 333 (44.4)
Unknown 194 (25.9)
ER-status ERe 201 (26.8)
ERþ 548 (73.1)
Unknown 1 (0.1)
PR status PRe 239 (39.1)
PRþ 397 (52.2)
Unknown 60 (8.0)
HER2-status HER2e 623 (83.1)
HER2þ 58 (7.7)
Unknown 69 (9.2)
Triple-negative tumour Yes 141 (18.8)
No 514 (68.5)
Unknown 95 (17.7)
Postmenopausal Yes 277 (36.9)
No 455 (60.7)
Unknown 18 (2.4)
ER, oestrogen receptor; PR, progesterone receptor.
a High number of missings as nodal status was not prospectively
collected in each study.
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logistic regression correcting for ER-status and cT-
status was used to calculate the OR. Subgroup ana-
lyses based on menopausal status (pre/perimenopausal
versus postmenopausal as defined per trial and by age)
and hormone-receptor status (triple-negative tumours
which are more likely to achieve pCR versus all other
tumours with known receptor status) were pre-speci-
fied.[7] The null hypothesis that the effect sizes of the
intervention (ZA) did not differ significantly between
subgroups was tested by adding an interaction between
subgroup characteristics and treatment (neoadjuvant
CTþZA versus neoadjuvant CT alone) in the logistic
regression analyses. Statistical analyses were done using
SPSS (version 20.0 for Windows, IBM SPSS Statistics)
and R (package ’meta’, version 2.15.0, The R Founda-
tion for Statistical Computing).
3. Results
3.1. Patients
Demographics and tumour characteristics of the pooled
population are summarised in Table 1. A total of 735
and 552 patients were included for the pCRb and pCR
analysis respectively. pCRb data were available from
735 patients (CONSORT diagram: Fig. 1). The median
age of our pooled population was 48 (range 25e75).
Thirty seven percent of the included women were post-
menopausal (Supplementary file: definitions of post-
menopausal status in included studies). Seventy three
percent of the tumours were ER-positive and 8% were
Human Epidermal growth factor Receptor 2 (HER2)-
positive. Nineteen percent of the tumours were triple-
negative (Table 1).
3.2. Trial-level analysis
Study effects among trials were homogeneous (I2Z 0%,
pZ 0.44), and for this reasonafixed-effectsmodelwas used
for analysis. In the total pooled population of patients with
early BC, the addition of ZA to neoadjuvant CT did not
increase pCRb (ORZ 1.28, 95% confidence interval [CI]
0.84e1.97) or pCR (ORZ 1.39, 95% CI 0.79e2.48)
(Fig. 2A, B). pCR and pCRb were next investigated sepa-
rately in pre/perimenopausal and postmenopausal women.
A non-significant benefit of the addition of ZAwith regards
to pCR and pCRb was observed in postmenopausal pa-
tients (pCR: ORZ 2.69, 95% CI 0.87e8.33; pCRb: OR
1.99, 95% CI 0.90e4.39), but not in pre/perimenopausal
patients (pCR: ORZ 0.93, 95% CI 0.46e1.90; pCRb:
ORZ 1.07, 95% CI 0.62e1.86) (Fig. 2C, D).
3.3. Individual patient-data analysis
In the individual patient-data analysis, no difference in
pCRb or pCR rates with the addition of ZA wasobserved in the total study population (Table 2). How-
ever, a significantly greater proportion of post-
menopausal patients attained pCRb if treated with the
addition of ZA (10.8% versus 17.7%, OR 2.14, 95%
CI 1.01e4.55, pZ 0.048). For pCR, a tendency towards
better response after zoledronic administration (7.8%
versus 14.6%, OR e2.62, 95% CI 0.90e7.62, pZ 0.076)
was observed. However, the data were not sufficient to
show a significant interaction between the intervention
(ZA) and postmenopausal status as regards treatment
effect. (p-value for interactionZ 0.17). A post hoc
exploratory analysis based on age as a surrogate for
menopausal status suggested that the benefit of ZA
addition increases with age (Fig. 3). However, this
should be considered as highly exploratory as no sig-
nificant interaction was observed between the age cate-
gories and ZA treatment (p-value for interaction 0.46).
4. Discussion
In our meta-analysis we did not observe a benefit in the
pCR or pCRb rate in the overall patient population
when ZA was added to neoadjuvant CT in women with
clinical stage II/III BC. Our study provides the first data
indicating a statistically significant benefit of the addi-
tion of ZA to neoadjuvant CT on pCR in post-
menopausal patients with early BC. Our findings are in
concordance with observations in the adjuvant setting,
where the addition of ZA to systemic therapy has shown
Fig. 1. CONSORT diagram. pCR, pathological complete response.
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levels of reproductive hormones [1,8,9].
The precise biological mechanism that enables a
specific anti-tumour effect of ZA in patients with low
reproductive hormone levels is still unknown. Post-
menopausal women are known to have an increased
receptor activator of nuclear factor-kappa b ligand
(RANKL) to osteoprotegerin ratio, thereby promoting
osteoclastogenesis and accelerating bone turnover [10].
During bone resorption, growth factors and cytokines,
such as insulin-like growth factors and transforming
growth factor b, are released from the bone which may
stimulate proliferation and attract tumour cells [11].
Since, the main effect of ZA is inhibition of bone
resorption, this might explain why postmenopausal
women, with an increased bone turnover, benefit from
ZA therapy. Another explanation might be related to an
immunomodulatory effect of ZA. Low oestrogen levels
induce an inflammatory response with an increase in
immune cells such as macrophages and T-cells [12].
Tumour associated macrophages (TAM) or M2 mac-
rophages assist tumour progression [13,14]. Bisphosph-
onates reverse the TAM phenotype from pro-tumoural
M2 to tumouricidal M1 and help deplete these M2
macrophages [15]. In addition to this, in a preclinical
model it was observed that ZA was more toxic to human
macrophages rather than to BC cells [16]. A study by
Junankar et al. showed, using two-photon microscopy,
that outside of the skeleton bisphosphonates are likely
to be taken up by TAMs. They found that bisphosph-
onates initially binds to areas of micro-calcifications and
can be engulfed by TAMs [17]. This might be a mech-
anism through which ZA could affect primary breast
tumour growth. Furthermore, stimulated T-cells may
interact with antigen presenting cells, attack tumour
cells and express and secrete RANKL, which can
contribute to the anti-tumour effect of ZA.Consequently, the combination of a tumour microen-
vironment with increased immune cells, RANKL and
bone turnover, caused by oestrogen deprivation, might
explain why ZA has an anti-tumour effect when
administered as an adjunct to neoadjuvant CT that
appears restricted to postmenopausal patients. Several
other mechanisms have been proposed as explanation
for direct anti-tumour effects of ZA, such as direct
cytotoxic and pro-apoptotic effects [18]. Also, preclini-
cal studies have suggested that bisphosphonates may
inhibit tumour angiogenesis [19e22]. Clearly, more
research is warranted elucidating the potential direct
anti-tumour effects of ZA. In addition, it may also be
possible that ZA exerts indirect anti-tumour effects, via
its impact on the bone microenvironment. However, it is
unclear how changes in the bone microenvironment can
affect tumour decrease in the more distal breast. Bone
acts a reservoir for paracrine tumour suppressors such
as activin. Activin is inhibited by follistatin and inhibin,
which is decreased in postmenopausal women. Winter
et al. published exploratory data showing that the
activin inhibitor follistatin is decreased after short term
ZA treatment [23].
Another point of potential interest for further inves-
tigation is the exact timing of ZA. The preclinical mice
study by Ottewell et al. showed that infusion of ZA
24 h after doxorubicin infusion resulted in enhanced
abolishment of tumour growth, suggesting that ’prim-
ing’ with doxorubicin made cells more sensitive to anti-
tumoural effects of ZA [8]. In three of the four studies
included in our meta-analysis (JONIE, AZURE, Aft
et al.) ZA was infused directly after CT. In the NEO-
ZOTAC study ZA was infused directly after CT during
hospital admission or within 24 h by homecare. In the
latter study no significant difference was observed be-
tween the direct infusion and infusion 1 d later within
24 h [5]. In future studies it would be interesting to also
Fig. 2. Forest plots of the effects of zoledronic acid on pCR (1A, 1C, 1E) and pCRb (1B, 1D, 1F). Odds ratios are adjusted for T-status
and ER-status. ER, oestrogen receptor; pCR, pathological complete response; pCRb, pathological complete response in the breast; OR,
odds ratio; CI, confidence interval.
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effective than when given directly after CT infusion.
There are some limitations to our study. Our meta-
analysis relied on slightly differing definitions of
menopausal status as defined by each of the included
studies. As confirmation of our findings, we performed
an analysis based on individual patient age as a sur-
rogate for menopausal status which showed similar
results to the analyses using trial-defined menopausal
status. Although our study represents the largest
population to date, the sample size of our meta-
analysis was not sufficient to prove a significanteffect of ZA on pCR in breast and lymph nodes, as
this end-point was not collected in one of the included
studies. In addition, our data were not sufficient to
show statistical interaction between postmenopausal
status and ZA intervention as regards pCR, although
clear differences, consistent with findings in the adju-
vant setting, were found in favour of the post-
menopausal subset of patients. Therefore, based on the
data presented in our study, it cannot yet be conclu-
sively stated that ZA has a direct anti-tumour effect in
the neoadjuvant setting and survival analyses of the
studies have to be awaited.
Table 2
pCRb and pCR in the total population and subgroups of interest.
Chemotherapy only ChemotherapyþZA Odd’s ratio 95% CI
pCRb/total Percentage pCRb/total Percentage
pCR in breast
Total population 50/372 13.4% 60/363 16.5% 1.31 0.86e1.99
Postmenopausal patients 14/130 10.8% 25/141 17.7% 2.14 1.01e4.55a
Pre/peri menopausal patients 34/232 14.7% 34/214 15.9% 1.09 0.64e1.84
Triple-negative breast cancer 13/70 18.6% 22/67 32.8% 2.16 0.97e4.84
pCR
Total population 27/278 9.7% 36/274 13.1% 1.43 0.82e2.49
Postmenopausal patients 7/90 7.8% 15/103 14.6% 2.62 0.90e7.62
Pre/peri menopausal patients 19/178 10.7% 20/163 12.3% 1.13 0.57e2.25
Triple-negative breast cancer 9/52 17.3% 16/51 31.4% 2.00 0.78e5.17
pCRb, pathological complete response in the breast; ZA, zoledronic acid; pCR, pathological complete response; CI, confidence interval.
Data from the individual patient data analysis.
a Statistically significant.
J.R. Kroep et al. / European Journal of Cancer 54 (2016) 57e6362Further translational research is necessary and
ongoing in order to elucidate the specific anti-tumour
mechanism of ZA, especially concerning the alleged
immunomodulatory role, in order to select those pa-
tients that would benefit most from including ZA in
their treatment regimen. The NEOZOL study for
example, aims to evaluate changes in vascular endo-
thelial growth factor and gamma-delta T-cell activity
(NCT01367288) [24].
Another important remaining question is whether the
beneficial effect in postmenopausal women during neo-
adjuvant treatment will translate into improved survival,
especially in cases with triple-negative BC. Reduction of
dissemination in the bone microenvironment may pro-
vide survival benefit. As the data mature over the next
few years, an update of this meta-analysis with longFig. 3. pCRb on the basis on age in the individual patient data
analysis. P-value for interaction Z 0.46. pCRb, pathological
complete response in the breast; OR, odds ratio; CI, confidence
interval.term follow up results will hopefully provide a conclu-
sive answer to this.
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